116 results on '"Downing, Sean"'
Search Results
2. 2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)
3. The InSituPlex® Staining Method for Multiplexed Immunofluorescence Cell Phenotyping and Spatial Profiling of Tumor FFPE Samples
4. Supplementary Table 1 from A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
5. Supplementary Table S1. from Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
6. Supplementary Data from Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
7. Supplementary Figure 1 from A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
8. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy
9. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer
10. Improved Method for Inoculation of a Cell Suspension Into a Hollow Fiber Bioreactor
11. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
12. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
13. Isolation and Proteomic Analysis of Platelets by SELDI-TOF MS
14. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
15. Abstract 4986: Utilizing image analysis to characterize an 8-plex immunofluorescence immune checkpoint biomarker panel within the tumor tissue microenvironment
16. Abstract LB-275: Measuring concordance of CD8 and PD-L1 expression in non-small cell lung cancer between a novel multiplex immunofluorescence assay and a brightfield laboratory developed test
17. Abstract 4989: Introduction of a robust workflow for the whole-side acquisition and co-registration of multiplex immunofluorescence tissue images for analysis of a 9-color, 8-marker immunophenotyping assay
18. Colchicine, aspirin, and montelukast – A case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19
19. Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data
20. Mutations in Ribonuclease L Gene Do Not Occur at a Greater Frequency in Patients with Familial Prostate Cancer Compared with Patients with Sporadic Prostate Cancer
21. Mutations in Ribonuclease L Gene Do NotOccur at a Greater Frequency in Patients with Familial Prostate Cancer Compared with Patients with Sporadic Prostate Cancer
22. Abstract 1677: Understanding the TME: Advanced analysis and visualization of multiplexed fluorescence images
23. Abstract 4569: Intra- and inter-run assessment of reproducibility and quantification of UltiMapper™ I/O APC and T-act kits for tissue multiplexing
24. Development of a PD-L1 multiplex immunofluorescence assay with advanced visual analysis for understanding the tumor microenvironment.
25. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: a review of the evidence
26. Colchicine, aspirin, and montelukast – A case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19.
27. Abstract 5652: Validation of novel InSituPlex™ technology utilizing standard chromogenic IHC and multiplexed tyramide-based immunofluorescence
28. Abstract 5657: Use of a novel immunofluorescence multiplexing technology, InSituPlex™, for the simultaneous detection of immune cells in multiple cancer types
29. Preliminary correlative analysis of PD-L1 expression from the SUNRISE study.
30. New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay
31. Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test
32. Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy
33. Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience.
34. Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies
35. A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
36. Functional status of mutant p53 proteins found in prostate cancer and their contribution to metastatic disease
37. Abstract B122: A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
38. Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples.
39. Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer.
40. Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
41. Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
42. Abstract 2279: Bringing next generation sequencing (NGS) to the clinic: Analytical validation of a comprehensive NGS-based cancer gene test.
43. Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).
44. Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.
45. Abstract 5074: Massively parallel DNA-sequencing of aggressive prostate cancer reveals disease heterogeneity and identifies targetable mutations
46. Abstract 967: Massively parallel sequencing of clinical FFPE cancer specimens enables comprehensive genomic assessment of patient eligibility for targeted therapy
47. Abstract C22: Massively parallel DNA-sequencing of aggressive prostate cancer reveals disease heterogeneity and identifies targetable mutations
48. Functional status of mutant p53 proteins found in prostate cancer and their contribution to metastatic disease
49. Isolation and Proteomic Analysis of Platelets by SELDI-TOF MS.
50. Elevated levels of prostate‐specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.